Researchers at The University of Sydney have identified a significant increase in melanoma-related death risk for patients with thin primary tumors measuring between 0.8 and 1.0 millimeters compared to those with thinner lesions.
Of Interest
A European project led by IDIBAPS-Hospital Clínic Barcelona studies the efficacy of immunotherapy for childhood melanoma for the first time
Conducted as part of the MELCAYA project, the study demonstrates that anti PD-1 antibody immunotherapy is safe for children and adolescents. Furthermore, whilst it is effective for patients who have previously had their tumour removed, its effectiveness is diminished in more advanced cases, where metastasis has already spread to other organs.
MMS-I Treatment Is Linked to Low Recurrence, Mortality in Head and Neck Melanoma
Mohs micrographic surgery with melanocytic immunostains (MMS-I) is emerging as an effective treatment option for invasive melanomas, particularly in anatomically constrained areas, due to a low risk of local recurrence and disease-specific mortality, according to study results published in Dermatologic Surgery.
Blood or Marrow Transplant Recipients Face High Risk for Skin Cancer
Survivors of blood or marrow transplant (BMT) face a significant risk of developing cutaneous malignant neoplasms, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma, with a cumulative incidence of 27.4% over 30 years, according to the results of a cohort study.